Loss of functional mitochondrial complex I (MCI) in the dopaminergic neurons of the substantia
nigra is a hallmark of Parkinson’s disease 1 . Yet, whether this change contributes to …

Disruption of neurotransmitter vesicle dynamics (transport, capacity, release) has been
implicated in a variety of neurodegenerative and neuropsychiatric conditions. Here, we report a …

Monoamine oxidase (MAO) metabolizes cytosolic dopamine (DA), thereby limiting auto-oxidation,
but is also thought to generate cytosolic hydrogen peroxide (H 2 O 2 ). We show that …

Members of the synaptic vesicle glycoprotein 2 (SV2) family of proteins are involved in
synaptic function throughout the brain. The ubiquitously expressed SV2A has been widely …

Disrupted-in-schizophrenia 1 (DISC1) is a mental illness gene first identified in a Scottish
pedigree. So far, DISC1-dependent phenotypes in animal models have been confined to …

The synaptic vesicle glycoprotein 2 (SV2) family is comprised of three paralogues: SV2A,
SV2B, and SV2C. In vertebrates, SV2s are 12-transmembrane proteins present on every …

Active transport of neurotransmitters into synaptic vesicles is required for their subsequent
exocytotic release. In the monoamine system, this process is carried out by the vesicular …

The psychostimulant methamphetamine (METH) is highly addictive and neurotoxic to dopamine
terminals. METH toxicity has been suggested to be due to the release and accumulation …

In the last several decades polybrominated diphenyl ethers (PBDEs) have replaced the
previously banned polychlorinated biphenyls (PCBs) in multiple flame retardant utilities. As …

The vesicular monoamine transporter 2 (VMAT2) packages neurotransmitters for release
during neurotransmission and sequesters toxicants into vesicles to prevent neuronal damage. …